Clinical importance of myeloid antigen expression in Moroccan patients with adult B-lineage acute lymphoblastic leukemia

Neoplasma

Volumn 60, Issue 5, 2013, Pages 553-560

  Lahjouji, A ^a   Bachir, F ^a   Bennani, S ^a   Benchekroun, S ^b   Amzazi, S ^c   Aouad, R E ^a  

^a INSTITUT NATIONAL D HYGIÈNE   (Morocco)

^b IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

^c MOHAMMED V UNIVERSITY   (Morocco)

Author keywords

Adult B acute lymphoblastic leukemia; Immunophenotyping; Myeloid antigen; Prognosis

Indexed keywords

CD19 ANTIGEN; CD22 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MYELOID ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANEMIA; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CHROMOSOME ANALYSIS; FEMALE; FOLLOW UP; HEPATOMEGALY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; RETROSPECTIVE STUDY; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOSYNTHESIS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MOROCCO; MORTALITY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD13; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOROCCO; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SIALIC ACID BINDING IG-LIKE LECTIN 3; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84891697099     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2013_072     Document Type: Article

References (23)

1. BASSO G, BULDINI B, DE ZL, ORFAO A. New methodologic approaches for immunophenotyping acute leukemias. Haematologica 2001; 86: 675-692.
2. HRUSAK O, PORWIT-MACDONALD A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002; 16: 1233-1258. http://dx.doi.org/10.1038/sj.leu.2402504
3. MACEDO A, ORFAO A, VIDRIALES MB, LOPEZ-BERGES MC, VALVERDE B, et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol 1995; 70: 189-194. http://dx.doi.org/10.1007/BF01700374
4. SCHABATH R, RATEI R AND LUDWIG W. The prognostic significance of antigen expression in leukaemia. Best Practice & Research Clinical Haematology 2003; 16: 613-628. http://dx.doi.org/10.1016/S1521-6926(03)00087-2
5. LUDWIG WD, HAFERLACH T & SCHOCH C. Classification of acute leukemias: perspective 1. In Pui CH (ed.) Treatment of Acute Leukemias: New Directions for Clinical Research. Totowa, NJ: Humana Press Inc, 2003, pp 3-41.
6. BENNETT JM, CATOVSKY D, DANIEL MT, FLANDRIN G, GALTON DA, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-8. http://dx.doi.org/10.1111/j.1365-2141.1976.tb03563.x
7. BENE MC, CASTOLDI G, KNAPP Wet al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-1786.
8. KAPLAN ER, MEIER P Non-parametric estimation from in complete observations. J Am Stat Assoc 1958; 53: 457-481 http://dx.doi.org/10.1080/01621459.1958.10501452
9. PETO R, PIKE MC: Conservatism of the approximation (O-E)2/E in the log-rank test for survival data or tumour incidence data. Biometrics 1973; 29: 579-584. http://dx.doi.org/10.2307/2529177
10. BEHM F. Classification of acute leukemias: perspective 2. In Pui CH (ed.) Treatment of Acute Leukemias: New Directions for Clinical Research. Totowa, NJ: Humana Press Inc, 2003, pp 43-58.
11. WHO, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001.
12. BENÉ MC, BERNIER M, CASASNOVAS RO et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 1998; 92: 596-599.
13. LAPORT GF, LARSON RA Treatment of acute lymphoblastic leukemia in adults. Semin Oncol 1997; 24: 70-82.
14. CZUCZMAN MS, DODGE RK, STEWART CC, et al Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8364. Blood 1999; 93: 3931-3939.
15. HANSON CA, ABAZA M, SHELDON S et al. Acute biphenotypic leukemia: immunophenotypic and cytogenetic analysis. British Journal of Haematology 1993; 84: 49-60. http://dx.doi.org/10.1111/j.1365-2141.1993.tb03024.x
16. DREXLER HG & LUDWIG WD. Incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Recent Results in Cancer Reseach 1993; 131: 53-66. http://dx.doi.org/10.1007/978-3-642-84895-7_6
17. KHALIDI HS, CHANG KL, MEDEIROS LJ et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. American Journal of Clinical Pathology 1999; 111: 467-476.
18. LUDWIG WD, RAGHAVACHAR A & THIEL E. Immunophenotypic classification of acute lymphoblastic leukemia. Baillie're's Clinical Haematology 1994; 7: 235-262. http://dx.doi.org/10.1016/S0950-3536(05)80201-X
19. UCKUN FM, SATHER HN, GAYNON PS et al. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 1997; 90: 28-35.
20. PUTTI MC, RONDELLI R, COCITO MG et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood 1998; 92: 795-801.
21. PUI CH, RUBNITZ R, HANCOCK ML et al. Reappraisal of the clinical and biologic significance of myeloidassociated antigen expression in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 1998; 16: 3768-3773.
22. LUDWIG WD, HARBOTT J, BARTRAM CR et al. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86. Recent Results in Cancer Research 1993; 131: 269-282. http://dx.doi.org/10.1007/978-3-642-84895-7_24
23. LUDWIG WD, HARBOTT J, RIEDER H, et al. Incidence, biologic features and treatment outcome of myeloidantigenpositive acute lymphoblastic leukemia (My {thorn} ALL). In Buchner T, et al. (eds) Acute Leukemias IV. Prognostic Factors. Berlin: Springer, 1994, pp 24. http://dx.doi.org/10.1007/978-3-642-78350-0_4